Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Diabetic Neuropathy

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Functional and anatomical outcomes for intravitreal bevacizumab treatment of choroidal neovascularization in a patient with angioid streaks.

Retinal cases & brief reports·2014

Same author

Metabolic control and diabetic retinopathy.

Current diabetes reviews·2009

Same author

Diabetic retinopathy and angiogenesis.

Current diabetes reviews·2009

Same author

Ischemic optic neuropathy.

Seminars in neurology·2007

Same author

Novel mutations in FRMD7 in X-linked congenital nystagmus. Mutation in brief #963. Online.

Human mutation·2007

Same author

Neurite outgrowth in retinal ganglion cell culture.

Methods in molecular biology (Clifton, N.J.)·2006

Search research articles

Related Experiment Videos

Ranibizumab for diabetic retinopathy.

Monica Rodriguez-Fontal¹, Virgil Alfaro, John B Kerrison

¹Charleston Neuroscience Institute, Retina Division, Charleston, SC 29414, USA. mrfontal@gmail.com

Current Diabetes Reviews

|February 10, 2009

Summary

Ranibizumab (Lucentis) effectively treats retinal diseases by inhibiting vascular endothelial growth factor (VEGF). Intraocular injections reduced retinal thickness and improved visual acuity in pilot studies, showing promise for conditions like diabetic retinopathy.

Related Experiment Videos

Area of Science:

Ophthalmology
Medical Research
Pharmacology

Background:

Retinal and choroidal vascular diseases are leading causes of vision loss.
Vascular Endothelial Growth Factor (VEGF) is implicated in the pathogenesis of these conditions.
Current treatments for some of these diseases, like diabetic retinopathy, are invasive.

Purpose of the Study:

To evaluate the efficacy of ranibizumab (Lucentis) in treating retinal and choroidal vascular diseases.
To assess ranibizumab's potential as an alternative therapy for proliferative diabetic retinopathy and neovascular glaucoma.
To investigate the role of anti-VEGF therapy in managing conditions characterized by neovascularization.

Main Methods:

Administration of intraocular injections of ranibizumab (Lucentis).
Pilot studies to assess changes in retinal thickness and Best Corrected Visual Acuity (BCVA).
Evaluation of ranibizumab's effect in animal models of proliferative retinopathy and neovascular glaucoma.

Main Results:

Intraocular ranibizumab injections led to decreased mean retinal thickness.
Pilot studies demonstrated improvement in BCVA in all subjects treated with ranibizumab.
Animal models indicated high sensitivity of neovascularizations to anti-VEGF therapy.

Conclusions:

Ranibizumab (Lucentis) shows significant potential as a VEGF inhibitor for treating retinal vascular diseases.
The drug demonstrated positive effects on retinal thickness and visual acuity in early studies.
Further clinical trials are expected to clarify the role of ranibizumab in treating conditions like diabetic macular edema (DME).